# A Study Assessing the Effect of RO4607381 on Vascular Function in Patients With Coronary Heart Disease (CHD) or CHD-Risk Equivalent Patients

> **NCT00655538** · PHASE2 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 476 (actual)

## Conditions studied

- Coronary Heart Disease

## Interventions

- **DRUG:** Placebo
- **DRUG:** dalcetrapib

## Key facts

- **NCT ID:** NCT00655538
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-02
- **Primary completion:** 2010-05
- **Final completion:** 2010-05
- **Target enrollment:** 476 (ACTUAL)
- **Last updated:** 2020-01-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00655538

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00655538, "A Study Assessing the Effect of RO4607381 on Vascular Function in Patients With Coronary Heart Disease (CHD) or CHD-Risk Equivalent Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00655538. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*